EGFR and non-small cell lung carcinoma: However, the factor(s) that we think will be important for drug activity based on preclinical models may end up not being the ideal or relevant target, as was the case with EGFR IHC expression for EGFR TKIs in NSCLC and for cetuximab in colorectal cancer [137].